These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 3321820)

  • 1. Treatment of Graves' ophthalmopathy with high-dose intravenous methylprednisolone pulse therapy.
    Nagayama Y; Izumi M; Kiriyama T; Yokoyama N; Morita S; Kakezono F; Ohtakara S; Morimoto I; Okamoto S; Nagataki S
    Acta Endocrinol (Copenh); 1987 Dec; 116(4):513-8. PubMed ID: 3321820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of steroid pulse therapy with and without orbital radiotherapy on Graves' ophthalmopathy.
    Ohtsuka K; Sato A; Kawaguchi S; Hashimoto M; Suzuki Y
    Am J Ophthalmol; 2003 Mar; 135(3):285-90. PubMed ID: 12614743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of high-dose intravenous steroid pulse therapy followed by 3-month oral steroid therapy for Graves' ophthalmopathy.
    Ohtsuka K; Sato A; Kawaguchi S; Hashimoto M; Suzuki Y
    Jpn J Ophthalmol; 2002; 46(5):563-7. PubMed ID: 12457917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous methylprednisolone pulse therapy for Graves' ophthalmopathy.
    Hiromatsu Y; Tanaka K; Sato M; Kuroki T; Nonaka K; Kojima K; Nishimura H; Nishida H; Kaise N
    Endocr J; 1993 Feb; 40(1):63-72. PubMed ID: 7951498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of Grave's ophthalmopathy with high doses of corticosteroids].
    Cirić J; Zarković M; Stojanović M; Pepenezić Z; Randjelović G; Gligorović M; Trbojević B; Drezgić M; Nesović M
    Srp Arh Celok Lek; 2000; 128(5-6):179-83. PubMed ID: 11089418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous methylprednisolone pulse therapy in the treatment of Graves' ophthalmopathy.
    Matejka G; Vergès B; Vaillant G; Petit JM; Brun-Pacaud A; Rudoni S; Brun JM
    Horm Metab Res; 1998 Feb; 30(2):93-8. PubMed ID: 9543692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy.
    Colao A; Lastoria S; Ferone D; Pivonello R; Macchia PE; Vassallo P; Bonavolonta G; Muto P; Lombardi G; Fenzi G
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3790-4. PubMed ID: 9814448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of life assessment in patients with Graves' disease and progressive infiltrative ophthalmopathy during combined treatment with methylprednisolone and orbital radiotherapy.
    Kulig G; Andrysiak-Mamos E; Sowińska-Przepiera E; Kulig J; Karakiewicz B; Brodowski J; Robaczyk M; Homa K; Letkiewicz M; Syrenicz A
    Endokrynol Pol; 2009; 60(3):158-65. PubMed ID: 19569015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone.
    Bartalena L; Marcocci C; Chiovato L; Laddaga M; Lepri G; Andreani D; Cavallacci G; Baschieri L; Pinchera A
    J Clin Endocrinol Metab; 1983 Jun; 56(6):1139-44. PubMed ID: 6341388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prediction for effectiveness of steroid pulse therapy by MRI in Graves' ophthalmopathy].
    Sato M; Hiromatsu Y; Tanaka K; Nonaka K; Kojima K; Nishimura H; Nishida H
    Nihon Naibunpi Gakkai Zasshi; 1992 Mar; 68(3):143-53. PubMed ID: 1582520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy of Graves' ophthalmopathy with intravenous high-dose steroid followed by orbital irradiation.
    Koshiyama H; Koh T; Fujiwara K; Hayakawa K; Shimbo S; Misaki T
    Thyroid; 1994; 4(4):409-13. PubMed ID: 7711503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose intravenous steroid pulse therapy in thyroid-associated ophthalmopathy.
    Tagami T; Tanaka K; Sugawa H; Nakamura H; Miyoshi Y; Mori T; Nakao K
    Endocr J; 1996 Dec; 43(6):689-99. PubMed ID: 9075609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.
    Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Rocchi R; Barbesino G; Mazzi B; Bartolomei MP; Lepri P; Cartei F; Nardi M; Pinchera A
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3562-7. PubMed ID: 11502779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orbital gallium-67 scintigraphy in Graves' ophthalmopathy.
    Konuk O; Atasever T; Unal M; Ayvaz G; Yetkin I; Cakir N; Arslan M; Hasanreisoglu B
    Thyroid; 2002 Jul; 12(7):603-8. PubMed ID: 12193305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of Graves' ophthalmopathy with oral or intravenous corticosteroids].
    Brauer VF; Scholz GH
    Med Klin (Munich); 2004 Feb; 99(2):71-6. PubMed ID: 14963657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orbital cobalt irradiation combined with retrobulbar or systemic corticosteroids for Graves' ophthalmopathy: a comparative study.
    Marcocci C; Bartalena L; Panicucci M; Marconcini C; Cartei F; Cavallacci G; Laddaga M; Campobasso G; Baschieri L; Pinchera A
    Clin Endocrinol (Oxf); 1987 Jul; 27(1):33-42. PubMed ID: 3308192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationships of orbital computed tomographic findings and activity scores to the prognosis of corticosteroid therapy in patients with Graves' ophthalmopathy.
    Chang TC; Huang KM; Hsiao YL; Tzeng SS; Kao SC
    Acta Ophthalmol Scand; 1997 Jun; 75(3):301-4. PubMed ID: 9253980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic responses to corticosteroids in Graves' ophthalmopathy.
    Chang TC; Kao SC; Hsiao YL; Lu CP; Huang KM; Tzeng SS
    J Formos Med Assoc; 1996 Nov; 95(11):833-8. PubMed ID: 8990770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy.
    Wiersinga WM
    Lancet Diabetes Endocrinol; 2017 Feb; 5(2):134-142. PubMed ID: 27346786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orbital gallium-67 scintigraphy in Graves' ophthalmopathy: a disease activity parameter that predicts the therapeutic response to immunosuppressive treatment.
    Konuk O; Atasever T; Unal M; Ayvaz G; Yetkin I; Cakir N; Arslan M; Hasanreisoglu B
    Thyroid; 2005 Apr; 15(4):358-63. PubMed ID: 15876160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.